NEFL and sarcopenia: Since, NF-L has been widely addressed for the follow-up of drugs targeting multiple sclerosis with encouraging results [41], the use of NF-L, in combination with a panel of other muscle-specific biomarkers, might represent an interesting opportunity for the follow-up and the overall comprehension of neurological aspects linked to sarcopenia.